Table 2.
Survivors (n = 24) | Non-survivors (n = 14) | p-value | |
---|---|---|---|
Gender | |||
Male | 11 | 5 | |
Female | 13 | 9 | 0.542 |
Underlying disease | |||
AIDS | 0 | 1 | 0.368 |
Diabetes mellitus | 9 | 6 | 0.744 |
Liver cirrhosis | 1 | 2 | 0.542 |
Hematologic disorders | 4 | 1 | 0.633 |
Autoimmune disorders | 1 | 2 | 0.542 |
Malignancy | 3 | 3 | 0.650 |
Chronic obstructive pulmonary disease | 1 | 4 | 0.052 |
Adrenal insufficiency | 3 | 4 | 0.387 |
Immunocompromised state | 7 | 10 | 0.011 |
Initial presentation | |||
Headache | 11 | 6 | 0.859 |
Altered consciousness | 17 | 12 | 0.438 |
Fever | 11 | 10 | 0.126 |
Seizure | 4 | 2 | 1.000 |
Visual disturbance | 1 | 0 | 1.000 |
Hearing impairment | 0 | 1 | 0.368 |
Cerebrospinal fluid data | |||
White blood cell count (109/L) | 0.09 | 0.09 | 0.950 |
Glucose (mmol/L) | 2.77 | 3.21 | 0.664 |
Protein (g/L) | 2.65 | 2.32 | 0.835 |
Lactate (mmol/L) | 5.36 | 5.34 | 0.982 |
Positive India ink stain | 3 | 6 | 0.050 |
Cryptococcal Ag titer (≥1024) | 5 | 7 | 0.071 |
Positive culture result | 16 | 10 | 0.711 |
Serum cryptococcal antigen titer (≥1024) | 5 | 7 | 0.130 |
Cryptococcemia | 2 | 7 | 0.006 |
Extraneural involvement | 3 | 2 | 1.000 |
Image finding | |||
Basal meningeal enhancement | 8 | 4 | 1.000 |
Pseudocyst/VR space dilatation | 10 | 4 | 0.365 |
Hydrocephalus | 9 | 6 | 0.823 |
Recent cerebral infarction | 5 | 6 | 0.268 |
Cryptococcoma | 1 | 0 | 1.000 |
AIDS acquired immunodeficiency syndrome, Ag antigen, VR Virchow-Robin